The Patent Finder
KH

Kyowa Hakko Bio Co., Ltd.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

54 patents currently held

23 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2027. from the record

Of the 23 now held by other companies, 15 name Plumino Precision Fermentation Holdings Pte Ltd. as their current owner, and 8 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
18
Ending by 2030
Mar 2027
Next term end
45
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Agent for Preventing or Improving Decline in Brain Function US 10,905,705
Cited by 6 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Ends Oct 2033 · Medium confidence
Also notable
Administration of Citicoline to Improve Cognitive Performance, Attentional Performance, and Motor Function US 11,583,546
Granted 2023. Computed term ends 2035.
Ends Nov 2035 · High confidence
Also notable
Rapid-Acting, Blood-Arginine-Level-Increasable Oral Preparation Comprising Citrulline and Arginine US 8,609,735
The largest patent family in this portfolio, 5 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Ends Sep 2029 · High confidence

Formerly held, still cited

Notable
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2030.
Ends Jan 2030 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 23 to 25, 2026 · next Dec 23
  • 1 fee due Jan 14, 2027
    The maintenance fee for Process for the Production of Dipeptides by a Dipeptide-Synthesizing Enzyme (US 9,081,199) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
  • 4 fees due Feb 6 to 28, 2027 · next Feb 6
  • 2 fees due Mar 1 to 10, 2027 · next Mar 1
  • 1 fee due Apr 1, 2027
    The maintenance fee for Method to Enhance Endurance (US 10,426,813) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
  • 1 fee due Jul 26, 2027
    The maintenance fee for Crystalline Oxidized Glutathione and Production Method Therefor (US 9,243,029) comes due Jul 26, 2027. Unpaid by Jan 26, 2028, it lapses early.
  • 1 fee due Aug 2, 2027
    The maintenance fee for Process for Production of Reduced Glutathione (US 9,249,517) comes due Aug 2, 2027. Unpaid by Feb 2, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,153,692Oral Preparation for Preventing or Improving Skin Dryness
In force
 · High confidence
In forceHigh confidence
US 7,932,288Composition for Relieving Subjective Symptoms of Fatigue
In force
 · High confidence
In forceHigh confidence
US 8,685,914L-Alanyl-L-Glutamine Crystal
In force
 · High confidence
In forceHigh confidence
US 8,067,537Composition and Method for Treatment of Stomatitis
In force
 · High confidence
In forceHigh confidence
US 8,188,308Crystal of Glutathione and Process for Production Thereof
In force
 · High confidence
In forceHigh confidence
US 9,060,980Rapid-Acting, Blood-Arginine-Level-Increasable Oral Preparation Comprising Citrulline and Arginine
In force
 · High confidence
In forceHigh confidence
US 9,622,998Rapid-Acting, Blood-Arginine-Level-Increasable Oral Preparation Comprising Citrulline and Arginine
In force
 · High confidence
In forceHigh confidence
US 10,052,298Rapid-Acting, Blood-Arginine-Level-Increasable Oral Preparation Comprising Citrulline and Arginine
In force
 · High confidence
In forceHigh confidence
US 8,679,568Citrulline-Containing Beverage
In force
 · High confidence
In forceHigh confidence
US 9,375,479Citrulline Containing Beverage
In force
 · High confidence
In forceHigh confidence
10 of 54 patents shown.
Pro members see all 54.
Pro members: see all 54 patents
Also on record, not counted in the 54: 23 patents in force now held by others · 55 patents ended · 20 applications pending · 75 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited